Mineralys Therapeutics (MLYS) Net Equity Issued and Repurchased (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Net Equity Issued and Repurchased of $188.9 million for Q2 2025, up 193.05% sequentially from -$203.0 million in Q4 2023.
Mineralys Therapeutics (MLYS) Net Equity Issued and Repurchased (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $188.9 million in Q2 2025.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $188.9 million in Q2 2025, while the trailing twelve-month figure through Mar 2026 was $188.9 million (changed N/A YoY) and the FY2025 annual result came in at $188.9 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased grew to $188.9 million in Q2 2025 per MLYS's latest filing, from -$203.0 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $203.6 million in Q1 2023 and troughed at -$203.0 million in Q4 2023.
- A 3-year average of $51.1 million and a median of $58.8 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
- The widest YoY moves for Net Equity Issued and Repurchased: up 271.71% in 2023, down 271.71% in 2023.
- Over 3 years, Net Equity Issued and Repurchased stood at $118.2 million in 2022, then slumped by 271.71% to -$203.0 million in 2023, then soared by 193.05% to $188.9 million in 2025.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $188.9 million, -$203.0 million, and -$581000.0 for Q2 2025, Q4 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 123.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 123.68 Mn |
| Jun 30, 2026 | 123.68 Mn |
| Mar 31, 2026 | 20.22 Mn |
| Mar 31, 2026 | 20.22 Mn |
| Dec 31, 2025 | -317,000.00 |
| Dec 31, 2025 | -317,000.00 |
| Sep 30, 2025 | 81.32 Mn |
| Sep 30, 2025 | 81.32 Mn |
| Jun 30, 2025 | 188.88 Mn |
| Jun 30, 2025 | 188.88 Mn |
| Dec 31, 2023 | -202.99 Mn |
| Dec 31, 2023 | -202.99 Mn |
| Jun 30, 2023 | -581,000.00 |
| Jun 30, 2023 | -581,000.00 |
| Mar 31, 2023 | 203.57 Mn |
| Mar 31, 2023 | 203.57 Mn |
| Dec 31, 2022 | 118.22 Mn |
| Dec 31, 2022 | 118.22 Mn |
| Sep 30, 2022 | -561,000.00 |
| Sep 30, 2022 | -561,000.00 |